Abstract: Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specifically binding to a); f) an antibody specifically binding to b); g) an antibody specifically binding to c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g). Pharmaceutical compositions and processes for making and using the compositions are also disclosed.
Type:
Application
Filed:
October 5, 2023
Publication date:
February 29, 2024
Applicant:
Board of Regents, The University of Texas System
Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
Type:
Application
Filed:
September 7, 2023
Publication date:
February 29, 2024
Applicant:
Board of Regents, The University of Texas System
Abstract: A robotic exoskeleton including a back portion providing at least two degrees of freedom, two shoulder portions, each shoulder portion providing at least five degrees of freedom, two elbow portions, each elbow portion providing at least one degree of freedom, and two forearm portions, each forearm portion providing at least one degree of freedom.
Type:
Grant
Filed:
June 14, 2021
Date of Patent:
February 27, 2024
Assignee:
Board of Regents, The University of Texas System
Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.
Type:
Grant
Filed:
April 22, 2021
Date of Patent:
February 27, 2024
Assignees:
Board of Regents, The University of Texas System, Cardio Vol, I.LC
Inventors:
Jonathan W. Valvano, John Porterfield, Clay Heighten, Anil Kottam, Marc David Feldman, Aleksandra Borisovna Gruslova, Drew R. Nolen
Abstract: Compositions for treating a wellbore include an exothermic additive capable of initiating an exothermic event following contact with a carrier fluid. The exothermic additive can have a coating that delays the exothermic event after contact with the carrier fluid. Methods disclosed herein include emplacing a fluid loss treatment composition in an interval of a wellbore, the fluid loss treatment including: a metallic fluid loss additive; an exothermic additive; and a carrier fluid; and reacting the exothermic additive to initiate an increase in temperature in the interval of the wellbore above a melting point of the metallic fluid loss additive; and converting the metallic fluid loss additive to a molten fluid loss additive; and treating the interval of the wellbore with the molten fluid loss additive.
Type:
Application
Filed:
October 19, 2021
Publication date:
February 22, 2024
Applicants:
Newpark Drilling Fluids LLC, Board of Regents, The University of Texas System
Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
Type:
Grant
Filed:
October 21, 2022
Date of Patent:
February 20, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
Abstract: A hybrid switched reluctance motor is provided that reduces torque ripple. A novel rotor design includes flux barriers. The flux barriers are positioned and shaped to create implicit saliency and reluctance torque for the motor. A gradual change in the motor reluctance results which avoids rapid increases in flux density. The rotor also increases efficiency by reducing acoustical and vibrational responses and associated energy loses.
Type:
Grant
Filed:
July 14, 2021
Date of Patent:
February 20, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Babak Fahimi, Seyed Ehsan Movahed Mohammadi, Mehdi Moallem
Abstract: In one aspect, the present disclosure relates to tumor associated macrophage (TAM) targeting peptide. In another aspect, the present disclosure relates to a method of targeting a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle. In yet another aspect, the present disclosure relates to a method of treating a tumor infiltrated with a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle.
Type:
Application
Filed:
December 20, 2021
Publication date:
February 15, 2024
Applicants:
Rutgers, The State University of New Jersey, Board of Regents, The University of Texas System
Abstract: Biodegradable antimicrobial films are provided that are solid at room temperature and substantially liquefy in situ after implantation into a mammal, such as a human patient. Methods of using the films to cover a medical device, such as a breast implant, prior to insertion into a subject are also provided.
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
February 13, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Joel Rosenblatt, Issam Raad, Andrew P. Dennis
Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
Type:
Grant
Filed:
December 7, 2022
Date of Patent:
February 13, 2024
Assignees:
Io Therapeutics, Inc., Board of Regents, The University of Texas System
Inventors:
Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
Abstract: Methods for generating fraud detection rules based on transaction data may include receiving historical transaction data, associating tags with each transaction, generating decision trees having root nodes and child nodes operably connected to the respective root nodes, determining at least one primary rule and at least one set of secondary rules associated with the at least one primary rule based on relationships between features of the transactions, assigning primary rules and sets of secondary rules to the at least one decision tree to populate the tree, extracting a plurality of rule sets including at least one primary rule and one or more secondary rules, determining an ordering of the plurality of rule sets; and determining a subset of rule sets from the ordered plurality of rule sets against which subsequently received transactions are compared against to determine if the subsequent transactions are fraudulent.
Type:
Grant
Filed:
March 4, 2022
Date of Patent:
February 13, 2024
Assignees:
Visa International Service Association, Board of Regents, The University of Texas System
Inventors:
Youxing Qu, Yiwei Cai, Dan Wang, Harishkumar Sundarji Majithiya, Roshni Ann Samuel, Susan Finnegan, Claudia Barcenas, Himanshu Chauhan
Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
Type:
Application
Filed:
November 17, 2022
Publication date:
February 8, 2024
Applicant:
Board of Regents, The University of Texas System
Inventors:
Michael A. CURRAN, Carlo TONIATTI, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Bianka PRINZ, Nadthakarn BOLAND
Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
Type:
Application
Filed:
June 15, 2023
Publication date:
February 8, 2024
Applicant:
The Board of Regents of The University of Texas System
Abstract: A pyrogenicity test method and assay of endotoxins allows for rapid and ultrahigh sensitivity testing of parenteral pharmaceuticals or medical devices that contact blood or cerebrospinal fluid by employing a Limulus Amoebocyte Lysate (LAL) assay monitored with a photonic-crystal biosensor. The photonic-crystal biosensor is capable of determining the presence of endotoxins in a test sample by detecting shifts in the resonant condition of an open microcavity affected by the changes in the refractive index of the analyte solutions used.
Type:
Grant
Filed:
May 10, 2021
Date of Patent:
February 6, 2024
Assignee:
Board of Regents, The University of Texas System
Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to MeCP2 loss and/or misfunction, including RETT syndrome. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a MeCP2 polypeptide.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
February 6, 2024
Assignee:
Board of Regents of the University of Texas System
Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.
Type:
Grant
Filed:
February 11, 2022
Date of Patent:
February 6, 2024
Assignee:
Board of Regents, The University of Texas System
Abstract: A diagnostic imaging device includes a probe that uses both an ultrasound transducer and frequency-domain diffuse optical imaging (FD-DOI) to assist with locating and diagnosing sub-tissue anomalies. According to one aspect, the diagnostic imaging device relates to a clip-on cap that can be utilized with existing ultrasound transducers. The diagnostic imaging device described herein can be utilized for image-guided needle biopsy to regions where prostate tissues are highly suspicious for high-grade cancer, as well as for image guided interventions, such as cryotherapy, photodynamic therapy, and brachytherapy for early-stage or localized prostate cancer.
Type:
Grant
Filed:
April 29, 2015
Date of Patent:
January 30, 2024
Assignee:
The Board of Regents of the University of Texas System
Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
Type:
Application
Filed:
June 15, 2023
Publication date:
January 25, 2024
Applicant:
The Board of Regents of The University of Texas System